Analyst consensus rating
Seres Therapeutics Analyst Rating: none
Direct answer
Seres Therapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.00.
Forecast evidence checked September 4, 2026.
Get free Seres Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.64
- Average price target
- $17.00
- High price target
- $22.00
- Low price target
- $12.00
- Low target gap
- +112.8%
- Target upside
- +201.4%
- High target gap
- +290.1%
- Target range width
- 177.3%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Seres Therapeutics?
Seres Therapeutics has a verified none consensus. The same dataset has an average price target of $17.00.
How far are Seres Therapeutics's low and high targets from the recorded price?
The low target implies +112.8%, while the high target implies +290.1%.
How many analysts are included in Seres Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Seres Therapeutics's target upside or downside calculated?
The average target of $17.00 is divided by the recorded price of $5.64, then one is subtracted to produce +201.4%. This does not guarantee a future return.
When was Seres Therapeutics's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.